Hexarelin CAS140703-51-1 2mg*vial

Product

Gonadorelin (GnRH) Peptide

  Hexarelin  

It is a synthetic hexapeptide that can promote the release of GH and is used clinically to treat the deficiency of growth hormone secretion.

Specifications

Gonadorelin Research

Background

Hexarelin (HEX) is a peptide GH secretagogue with a potent ability to stimulate GH secretion and recently reported cardioprotective actions. However, hexarelin (HEX) effects in the brain are largely unknown, and the aim of the present study was to examine the potential protective effect of hexarelin (HEX) on the central nervous system after injury, as well as on caspase-3, Akt, and extracellular signal-regulated protein kinase (ERK) signaling cascades in a rat model of neonatal hypoxia-ischemia.

 How does hexarelin work?

Hexarelin, a synthetic growth hormone-releasing peptide, can bind to and activate the growth hormone secretagogue receptor (GHSR) in the brain similar to its natural analog ghrelin.

Is hexarelin better than Ipamorelin?

Though the research remains to be done, it is a good bet that hexarelin is an excellent reliever of pain. Hexarelin benefits in the area of pain perception may be greater than those of ipamorelin given slight structural differences, but that remains to be demonstrated.

What is the mechanism of action of Hexarelin?

Three different mechanisms, not mutually exclusive, are postulated for Hexarelin stimulation of GH secretion in vivo: a direct action on the pituitary, though of minor relevance; an indirect action that involves release of GHRH, of relevance only in adult rats; and an action through the release of a still unknown ...

Does hexarelin increase cortisol?

Hexarelin significantly increased ACTH and cortisol release (area under the curve, 3,444 ± 696 ng/L·125 min and 45,844± 2,925 nmol/L·125 min, respectively), and this effect was augmented by the addition of CRH in a dose that on its own produces maximal stimulation (6,580 ± 1,572 ng/mL·125 min and 63,170 ± 2,616 nmol/L· 

References

1. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273:974–977. [PubMed] [Google Scholar]
2. Kojima M, Hosoda H, Matsuo H, et al. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab. 2001;12:118–122. [PubMed] [Google Scholar]
3. Lazarczyk MA, Lazarczyk M, Grzela T. Ghrelin: a recently discovered gut-brain peptide (review) Int J Mol Med. 2003;12:279–287. [PubMed] [Google Scholar]
4. Marleau S, Mulumba M, Lamontagne D, et al. Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies. Cardiovasc Res. 2006;69:26–35. [PubMed] [Google Scholar]
5. Leite-Moreira AF, Soares JB. Physiological, pathological and potential therapeutic roles of ghrelin. Drug Discov Today. 2007;12:276–288. [PubMed] [Google Scholar]
6. van der Lely AJ, Tschöp M, Heiman ML, et al. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev. 2004;25:426–457. [PubMed] [Google Scholar]
7. Nagaya N, Miyatake K, Uematsu M, et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab. 2001;86:5854–5859. [PubMed] [Google Scholar]
8. Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004;110:3674–3679. [PubMed] [Google Scholar]